ESR1 and Hypoglycemia: Documented effects of the intracerebroventricular (icv) delivery of ERα antagonist 1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride (MPP) or ERβ antagonist 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP) implicate these estrogen receptors (ERs) in forebrain mechanisms that govern VMN nNOS and GAD65/67 protein responses to hypoglycemia [30].